Will Eli Lilly and Company Become A Trillion-Dollar Baby?

Will Eli Lilly and Company Become A Trillion-Dollar Baby?

I initially rated Eli Lilly as a buy with a five-year target price of $1,020 per share in September 2023, based on its strong growth potential and valuation. Following the company’s impressive earnings report, I’ve revised my target price to $1,318, reflecting an 81.8% upside over the next 3-5 years, driven by robust demand for its blockbuster drugs, particularly the weight-loss drug Mounjaro. With accelerating earnings growth and a powerful stock chart, I now rate LLY as a Strong Buy and have positioned it as our second-largest holding behind Nvidia.